Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=260&ordering=end_planned
{ "count": 2329, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=280&ordering=end_planned", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=240&ordering=end_planned", "results": [ { "id": 1645, "title": { "de": "Influence of Antioxidative Agents like Resveratrol, Quercetin-dihydrate, and Seleno-L-Methionine on Human Synoviocytes of Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Psoriasis Arthritis (PsA) Patients", "en": "Influence of Antioxidative Agents like Resveratrol, Quercetin-dihydrate, and Seleno-L-Methionine on Human Synoviocytes of Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Psoriasis Arthritis (PsA) Patients" }, "short": "Influence of Antioxidative Agents", "url": null, "abstract": { "de": "Osteoarthritis is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on healthy human synovial cells compared to synovial cells from OA and RA patients. We propose that these chemo preventive agents cause a growth rate decrease in synovial tissue and furthermore an inhibition of proinflammatory factors as well as an increase in factors favouring apoptosis and cell death. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial cells. If the potency in decreasing inflammatory Interleukins is similar to the results of animal experiments, it would be an enormous effort for treatment of Osteoarthritis and Rheumatoid Arthritis. This study should be undertaken to define a possible systemic or local application of Resveratrol compared to Quercetin and Selenium. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods.\r\n", "en": "Osteoarthritis is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on healthy human synovial cells compared to synovial cells from OA and RA patients. We propose that these chemo preventive agents cause a growth rate decrease in synovial tissue and furthermore an inhibition of proinflammatory factors as well as an increase in factors favouring apoptosis and cell death. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial cells. If the potency in decreasing inflammatory Interleukins is similar to the results of animal experiments, it would be an enormous effort for treatment of Osteoarthritis and Rheumatoid Arthritis. This study should be undertaken to define a possible systemic or local application of Resveratrol compared to Quercetin and Selenium. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods.\r\n" }, "begin_planned": "2008-09-01T02:00:00+02:00", "begin_effective": "2008-08-01T02:00:00+02:00", "end_planned": "2009-08-31T02:00:00+02:00", "end_effective": "2010-08-31T02:00:00+02:00", "assignment": "2008-10-29T16:01:05+01:00", "program": 79, "subprogram": null, "organization": 14052, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1645-50696-12", "1645-57343-12" ] }, { "id": 1398, "title": { "de": "Neue Methode zur Beschleunigung der Knochenbruchheilung unter Zuhilfenahme von bioaktivem Glas, das mit Protein/Lipid-Peroxidationsprodukten beschichtet ist", "en": "Neue Methode zur Beschleunigung der Knochenbruchheilung unter Zuhilfenahme von bioaktivem Glas, das mit Protein/Lipid-Peroxidationsprodukten beschichtet ist" }, "short": "KNOCHENBRUCHHEILUNG_BIOAKTIV_GAS", "url": null, "abstract": { "de": "Fractures of long bones or large joints are followed by long lasting and often incomplete recovery in particular in elderly people and patients with multifragmentary fractures. Hoping to solve this difficult medical and social problem various experimental treatments are being developed using bioactive materials or substances that may stimulate bone growth.\r\n\r\nOn the contrary, patients with traumatic brain injury exert very short period of bone healing. Our clinical studies and the use of genuine model of human bone tissue cultures indicated that such enhanced osteogenesis is associated with the complex stress response involving lipid peroxidation. Studying molecular mechanisms of this phenomenon we found that the product of lipid peroxidation 4-hydroxynonenal (HNE) may regulate the growth of cultured human bone cells.\r\n\r\nTherefore, the aim of this project is to study in vitro possible use of HNE applied on bioactive glass for promotion of osteogenesis.", "en": "Fractures of long bones or large joints are followed by long lasting and often incomplete recovery in particular in elderly people and patients with multifragmentary fractures. Hoping to solve this difficult medical and social problem various experimental treatments are being developed using bioactive materials or substances that may stimulate bone growth.\r\n\r\nOn the contrary, patients with traumatic brain injury exert very short period of bone healing. Our clinical studies and the use of genuine model of human bone tissue cultures indicated that such enhanced osteogenesis is associated with the complex stress response involving lipid peroxidation. Studying molecular mechanisms of this phenomenon we found that the product of lipid peroxidation 4-hydroxynonenal (HNE) may regulate the growth of cultured human bone cells.\r\n\r\nTherefore, the aim of this project is to study in vitro possible use of HNE applied on bioactive glass for promotion of osteogenesis." }, "begin_planned": "2007-09-01T02:00:00+02:00", "begin_effective": "2007-09-01T02:00:00+02:00", "end_planned": "2009-08-31T02:00:00+02:00", "end_effective": "2009-08-31T02:00:00+02:00", "assignment": "2007-11-08T11:29:56+01:00", "program": 79, "subprogram": null, "organization": 14052, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 482, "title": { "de": "Defective DNA-Repair in acute myeloid leukemia", "en": "Defective DNA-Repair in acute myeloid leukemia" }, "short": "Defective DNA-Repair ", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2005-09-05T02:00:00+02:00", "begin_effective": "2005-09-05T02:00:00+02:00", "end_planned": "2009-09-03T02:00:00+02:00", "end_effective": "2009-09-03T02:00:00+02:00", "assignment": "2005-10-26T02:00:00+02:00", "program": null, "subprogram": null, "organization": 14082, "category": 10, "type": 10, "partner_function": 4, "manager": 51857, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 423 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "482-51857-10" ] }, { "id": 1900, "title": { "de": "Genom und Autismus", "en": "Genom und Autismus" }, "short": "GENOM_AUTISMUS", "url": null, "abstract": { "de": "Unser Konzept sieht vor, mit der etablierten Infrastruktur, bereits von Dr. Kaschnitz an der Universitätsklinik für Kinderheilkunde diagnostizierte Autismus PatientInnen gemäß den ADI (Autismus Diagnostik Interview)/ADOS (Diagnostische Beobachtungsskala für Autistische Störungen) Kriterien einzustufen, DNA aus peripherem Vollblut (ca. 5ml) zu isolieren und mittels modernster molekularer Methoden (Array-CGH) auf ASD-spezifische Kopienzahlvarianten (kleinste Verluste bzw. Zugewinne) im Erbgut zu untersuchen.", "en": "Unser Konzept sieht vor, mit der etablierten Infrastruktur, bereits von Dr. Kaschnitz an der Universitätsklinik für Kinderheilkunde diagnostizierte Autismus PatientInnen gemäß den ADI (Autismus Diagnostik Interview)/ADOS (Diagnostische Beobachtungsskala für Autistische Störungen) Kriterien einzustufen, DNA aus peripherem Vollblut (ca. 5ml) zu isolieren und mittels modernster molekularer Methoden (Array-CGH) auf ASD-spezifische Kopienzahlvarianten (kleinste Verluste bzw. Zugewinne) im Erbgut zu untersuchen." }, "begin_planned": "2009-08-10T02:00:00+02:00", "begin_effective": "2009-08-10T02:00:00+02:00", "end_planned": "2009-09-04T02:00:00+02:00", "end_effective": "2009-09-04T02:00:00+02:00", "assignment": "2009-08-24T13:45:59+02:00", "program": null, "subprogram": "Generation Innovation Praktika", "organization": 14021, "category": 10, "type": 10, "partner_function": 4, "manager": 51996, "contact": 51996, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": "824168", "ethics_committee": null, "edudract_number": null, "persons": [ "1900-51996-10" ] }, { "id": 1949, "title": { "de": "Smoking Genes", "en": "Smoking Genes" }, "short": "SMOKING GENES", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-09-01T02:00:00+02:00", "begin_effective": "2009-09-01T02:00:00+02:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2009-09-30T02:00:00+02:00", "assignment": "2009-10-15T16:40:00+02:00", "program": null, "subprogram": "Generation Innovation Praktika", "organization": 14028, "category": 10, "type": 10, "partner_function": 4, "manager": 50910, "contact": 50910, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": "824442", "ethics_committee": null, "edudract_number": null, "persons": [ "1949-50910-10" ] }, { "id": 1371, "title": { "de": "Interventionsprogramm für Eltern von Frühgeborenen; Eine Studie zur Optimierung der Entwicklung von Frühgeborenen", "en": "Interventionsprogramm für Eltern von Frühgeborenen; Eine Studie zur Optimierung der Entwicklung von Frühgeborenen" }, "short": "INTERVENTIONSPROG_FRUEHGEBORENE", "url": null, "abstract": { "de": "In der Steiermark werden im Jahr ca. 9000 Kinder geboren. Davon kommen ca. 10 Prozent zu früh auf die Welt. Hinsichtlich Entwicklungsstörungen sind Kinder mit einem Geburtsgewicht von unter 1500g besonders gefährdet, der Fachausdruck für diese Kinder lautet \"very low birth weight infants\". Diese Kinder weisen im jungen Erwachsenenalter im Vergleich zu ehemals reif geborenen Neugeborenen, einen niedrigeren Schulabschluss und eine geringere durchschnittliche kognitive Leistung auf. Zusätzlich haben sie häufiger soziale Schwierigkeiten im Umgang mit Gleichaltrigen.\r\nIn der vorliegenden Studie wird der Entwicklungsverlauf kleiner Frühgeborener (FG<= 32.SSW) im Zusammenhang mit einer - zur psychologischen Einzelbetreuung zusätzlichen - Gruppenbetreuung und einer ambulanten bzw. mobilen psychologischen Einzelbetreuung derer Eltern beobachtet und gemessen. Gleichzeitig sollten das individuelle Stressniveau und die Kontrollüberzeugung und mögliche Veränderungen durch ein frühzeitig ambulant-mobiles Interventionsprogramm der Mütter/Eltern von FG erhoben werden.", "en": "In der Steiermark werden im Jahr ca. 9000 Kinder geboren. Davon kommen ca. 10 Prozent zu früh auf die Welt. Hinsichtlich Entwicklungsstörungen sind Kinder mit einem Geburtsgewicht von unter 1500g besonders gefährdet, der Fachausdruck für diese Kinder lautet \"very low birth weight infants\". Diese Kinder weisen im jungen Erwachsenenalter im Vergleich zu ehemals reif geborenen Neugeborenen, einen niedrigeren Schulabschluss und eine geringere durchschnittliche kognitive Leistung auf. Zusätzlich haben sie häufiger soziale Schwierigkeiten im Umgang mit Gleichaltrigen.\r\nIn der vorliegenden Studie wird der Entwicklungsverlauf kleiner Frühgeborener (FG<= 32.SSW) im Zusammenhang mit einer - zur psychologischen Einzelbetreuung zusätzlichen - Gruppenbetreuung und einer ambulanten bzw. mobilen psychologischen Einzelbetreuung derer Eltern beobachtet und gemessen. Gleichzeitig sollten das individuelle Stressniveau und die Kontrollüberzeugung und mögliche Veränderungen durch ein frühzeitig ambulant-mobiles Interventionsprogramm der Mütter/Eltern von FG erhoben werden." }, "begin_planned": "2007-10-01T02:00:00+02:00", "begin_effective": "2007-10-01T02:00:00+02:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2010-09-30T02:00:00+02:00", "assignment": "2007-10-02T17:41:06+02:00", "program": null, "subprogram": null, "organization": 14094, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1371-50907-12", "1371-59859-11", "1371-51822-12", "1371-51643-11", "1371-51653-12" ] }, { "id": 2033, "title": { "de": "Mit autologen Thrombozyten angereichertes körpereigenes Fibrin zur Förderung der Wundheilung bei chronischem Ulcus cruris venosum (kontrollierte prospektive randomisierte klinische Studie)", "en": "Mit autologen Thrombozyten angereichertes körpereigenes Fibrin zur Förderung der Wundheilung bei chronischem Ulcus cruris venosum (kontrollierte prospektive randomisierte klinische Studie)" }, "short": " Ulcus cruris venosum Studie", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2008-10-01T02:00:00+02:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-01-12T17:36:20+01:00", "program": null, "subprogram": null, "organization": 14073, "category": 10, "type": 10, "partner_function": 4, "manager": 51612, "contact": 51612, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2033-51612-10" ] }, { "id": 864, "title": { "de": "PREGENESYS: Development of Early Non-Invasive Biomarkers and Means for the Diagnosis and Progression Monitoring of Preeclampsia and Tailoring Putative Therapies", "en": "PREGENESYS: Development of Early Non-Invasive Biomarkers and Means for the Diagnosis and Progression Monitoring of Preeclampsia and Tailoring Putative Therapies" }, "short": "PREGENESYS", "url": null, "abstract": { "de": "Preeclampsia (PET), de-novo hypertension & proteinuria after mid gestation, affects 5-7% of all pregnancies. Cases may develop life threatening haemolysis-elevated liver enzymes-low platelets (HELLP) or renal failure, cerebral haemorrhages & eclampsia, IUGR, placental abruption & death.\r\nWe will identify markers for PET risk prediction in the 1st trimester to allow longer time for tailoring putative medications to prevent PET, and assess & characterize plausible links between marker shortage/access, PET & putative medications in \"in-vitro\" systems to fit putative medications to pre-defined disease-risk women.\r\nWe will develop non-invasive diagnostic kits for 1st trimester PET prediction based on markers, antibodies, oligos & siRNA and others coupled to the power of Doppler ultrasound. Nested case-control clinical studies will test effectiveness of combined diagnosis & drug tailoring. A Trans European prospective clinical study, combining early diagnosis & randomising putative medication will verify findings.\r\nR&D results will be used to train physicians & patients, to implement new prenatal care practice and eradicate preeclampsia.", "en": "Preeclampsia (PET), de-novo hypertension & proteinuria after mid gestation, affects 5-7% of all pregnancies. Cases may develop life threatening haemolysis-elevated liver enzymes-low platelets (HELLP) or renal failure, cerebral haemorrhages & eclampsia, IUGR, placental abruption & death.\r\nWe will identify markers for PET risk prediction in the 1st trimester to allow longer time for tailoring putative medications to prevent PET, and assess & characterize plausible links between marker shortage/access, PET & putative medications in \"in-vitro\" systems to fit putative medications to pre-defined disease-risk women.\r\nWe will develop non-invasive diagnostic kits for 1st trimester PET prediction based on markers, antibodies, oligos & siRNA and others coupled to the power of Doppler ultrasound. Nested case-control clinical studies will test effectiveness of combined diagnosis & drug tailoring. A Trans European prospective clinical study, combining early diagnosis & randomising putative medication will verify findings.\r\nR&D results will be used to train physicians & patients, to implement new prenatal care practice and eradicate preeclampsia." }, "begin_planned": "2006-10-01T02:00:00+02:00", "begin_effective": "2006-12-01T01:00:00+01:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2009-11-30T01:00:00+01:00", "assignment": "2006-08-07T16:55:01+02:00", "program": 21, "subprogram": "Biowissenschaften", "organization": 14017, "category": 10, "type": 10, "partner_function": 2, "manager": 54142, "contact": 54142, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "864-54142-10", "864-50278-12" ] }, { "id": 1936, "title": { "de": "CII-AT-0042-04-0809 - Medical Imaging & Medical Information Processing", "en": "CII-AT-0042-04-0809 - Medical Imaging & Medical Information Processing" }, "short": "CEEPUS Medical Imaging", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2008-10-01T02:00:00+02:00", "begin_effective": "2008-10-01T02:00:00+02:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2009-09-30T02:00:00+02:00", "assignment": null, "program": null, "subprogram": null, "organization": 14106, "category": 10, "type": 10, "partner_function": 2, "manager": 51913, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1936-83445-12", "1936-51824-12", "1936-51709-12", "1936-51913-10" ] }, { "id": 1882, "title": { "de": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer", "en": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer" }, "short": "CHEMOTHERAP_BREAST CANCER", "url": null, "abstract": { "de": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis.", "en": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2010-09-30T02:00:00+02:00", "assignment": "2009-08-03T14:52:33+02:00", "program": null, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 4, "manager": 58814, "contact": 58814, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1882-58814-10" ] }, { "id": 1578, "title": { "de": "Whole Genome Screening des Menschen bei der Menigokokkensepsis", "en": "Whole Genome Screening des Menschen bei der Menigokokkensepsis" }, "short": "Meningokokkensepsis", "url": null, "abstract": { "de": "Meningokokkenerkrankungen betreffen fast immer vorher vollkommen gesunde Kinder und können innerhalb weniger Stunden zum Tod führen. Die Erkrankung ist selten, in Österreich werden jährlich zwischen 80 und 100 Fälle beobachtet. Betroffen sind fast ausschließlich Kinder. Die septische Verlaufsform ist durch die rasche Entwicklung eines schweren Schocks mit verminderter Durchblutung der Haut, Bewusstlosigkeit, Multiorganversagen und schwerer Stö-rung der Blutgerinnung charakterisiert, die Sterblichkeit liegt trotz intensivmedizinischer Bemü-hungen noch immer bei etwa 25%.\r\nEs sind nun Genomanalysen verfügbar, mit denen das gesamte menschliche Genom (3 Mrd. Basenpaare) untersucht werden kann. Mit diesen neuen Methoden können alle genetischen Än-derungen, die für das Auftreten und den Verlauf einer Erkrankung verantwortlich sind, unter-sucht werden. In den letzten 2 Jahren sind bereits mehrere solche whole genome association studies (GWAs) veröffentlicht worden, jedoch wurden noch keine Ergebnisse zur Genetik der Sepsis gezeigt.\r\nMit Hilfe unseres Netzwerkes wäre es uns möglich, mit zwei weiteren Forschungsgruppen eine Kooperation zur Klärung der genetischen Ursachen der Meningokokkensepsis zu etablieren. Das so gebildete Kollektiv würde das weltweit größte Netzwerk zur Untersuchung von Meningo-kokkenerkrankungen darstellen. Es würde über 3000 europäischen Patienten sowie 700 Kon-trollproben umfassen und sich aus einer britischen, niederländischen, sowie unserer mitteleuro-päischen Kohorte zusammensetzen.\r\nIn Summe würden sich bei dem von uns primär eingesetzten Probenkollektiv von 200-400 Pati-enten 220 440 Millionen Einzeluntersuchungen zur Darstellung des gesamten Genoms jeder einzelnen Patienten- bzw. Kontrollprobe ergeben.\r\nDas Ziel dieser weltweiten Kooperation ist es, die genetischen Variablen, welche zu einer Me-ningokokkensepsis führen, aufzudecken. Es soll so eine erste komplette Übersicht über die Ge-netik der Sepsiserkrankung erreicht werden. Die Aufklärung der involvierten Gene kann als An-gelpunkt für die weiterführende Forschung gesehen werden und bildet eine erste Grundlage für die Entwicklung selektiver (Kombinations-) Therapien.", "en": "Meningokokkenerkrankungen betreffen fast immer vorher vollkommen gesunde Kinder und können innerhalb weniger Stunden zum Tod führen. Die Erkrankung ist selten, in Österreich werden jährlich zwischen 80 und 100 Fälle beobachtet. Betroffen sind fast ausschließlich Kinder. Die septische Verlaufsform ist durch die rasche Entwicklung eines schweren Schocks mit verminderter Durchblutung der Haut, Bewusstlosigkeit, Multiorganversagen und schwerer Stö-rung der Blutgerinnung charakterisiert, die Sterblichkeit liegt trotz intensivmedizinischer Bemü-hungen noch immer bei etwa 25%.\r\nEs sind nun Genomanalysen verfügbar, mit denen das gesamte menschliche Genom (3 Mrd. Basenpaare) untersucht werden kann. Mit diesen neuen Methoden können alle genetischen Än-derungen, die für das Auftreten und den Verlauf einer Erkrankung verantwortlich sind, unter-sucht werden. In den letzten 2 Jahren sind bereits mehrere solche whole genome association studies (GWAs) veröffentlicht worden, jedoch wurden noch keine Ergebnisse zur Genetik der Sepsis gezeigt.\r\nMit Hilfe unseres Netzwerkes wäre es uns möglich, mit zwei weiteren Forschungsgruppen eine Kooperation zur Klärung der genetischen Ursachen der Meningokokkensepsis zu etablieren. Das so gebildete Kollektiv würde das weltweit größte Netzwerk zur Untersuchung von Meningo-kokkenerkrankungen darstellen. Es würde über 3000 europäischen Patienten sowie 700 Kon-trollproben umfassen und sich aus einer britischen, niederländischen, sowie unserer mitteleuro-päischen Kohorte zusammensetzen.\r\nIn Summe würden sich bei dem von uns primär eingesetzten Probenkollektiv von 200-400 Pati-enten 220 440 Millionen Einzeluntersuchungen zur Darstellung des gesamten Genoms jeder einzelnen Patienten- bzw. Kontrollprobe ergeben.\r\nDas Ziel dieser weltweiten Kooperation ist es, die genetischen Variablen, welche zu einer Me-ningokokkensepsis führen, aufzudecken. Es soll so eine erste komplette Übersicht über die Ge-netik der Sepsiserkrankung erreicht werden. Die Aufklärung der involvierten Gene kann als An-gelpunkt für die weiterführende Forschung gesehen werden und bildet eine erste Grundlage für die Entwicklung selektiver (Kombinations-) Therapien." }, "begin_planned": "2009-01-01T01:00:00+01:00", "begin_effective": "2008-07-17T02:00:00+02:00", "end_planned": "2009-10-31T01:00:00+01:00", "end_effective": "2010-05-31T02:00:00+02:00", "assignment": "2008-07-16T13:03:29+02:00", "program": null, "subprogram": null, "organization": 14091, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": 54004, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 977, "title": { "de": "Mutation distribution and identification of novel genes in hereditary neuropathies", "en": "Mutation distribution and identification of novel genes in hereditary neuropathies" }, "short": "GENETIK BEI HEREDITAEREN NEUROPATHIEN", "url": null, "abstract": { "de": "Hereditary neuropathies are one of the most frequently inherited causes of neurological disability with an estimated prevalence of 1 in 2500. Age at onset is usually during the first two decades of life or sometimes later. Molecular genetic examinations have shown marked genetic heterogenety with more than 30 genes identified. In some CMT patients and families the underlying gene still has to be found.\r\nIn this project we aim to recruit CMT patients and families in all parts of Austria. We will carry out detailed clinical, electrophysiological and genetic examinations and perform epidemiological studies. Further we aim to identify a novel gene locus in autosomal dominant HSN and MSN type 1.\r\nAnother important aim of this project is to utilize the already existing collaborations with other European groups to create a network with special focus on peripheral neuropathies.", "en": "Hereditary neuropathies are one of the most frequently inherited causes of neurological disability with an estimated prevalence of 1 in 2500. Age at onset is usually during the first two decades of life or sometimes later. Molecular genetic examinations have shown marked genetic heterogenety with more than 30 genes identified. In some CMT patients and families the underlying gene still has to be found.\r\nIn this project we aim to recruit CMT patients and families in all parts of Austria. We will carry out detailed clinical, electrophysiological and genetic examinations and perform epidemiological studies. Further we aim to identify a novel gene locus in autosomal dominant HSN and MSN type 1.\r\nAnother important aim of this project is to utilize the already existing collaborations with other European groups to create a network with special focus on peripheral neuropathies." }, "begin_planned": "2006-11-01T01:00:00+01:00", "begin_effective": "2006-11-01T01:00:00+01:00", "end_planned": "2009-10-31T01:00:00+01:00", "end_effective": "2011-03-31T02:00:00+02:00", "assignment": "2006-12-27T12:44:35+01:00", "program": 72, "subprogram": null, "organization": 14080, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P19455", "ethics_committee": null, "edudract_number": null, "persons": [ "977-51831-12" ] }, { "id": 1260, "title": { "de": "SFB: Mathematische Optimierung mit Anwendungen in der biomedizinischen Forschung\r\n1. Förderperiode", "en": "SFB: Mathematical Optimization with Applications in Biomedical Sciences" }, "short": "Mathematical Optimization", "url": "http://math.uni-graz.at/mobis/", "abstract": { "de": "In this project, a realistic computer model of the heart, a Virtual Heart simulator will be developed to investigate mechanisms underlying the formation of arrhythmias, the most frequent cause of death in the industrialized world, and their termination by electrical shocks (electrical defibrillation). During the first phase, research will focus on different aspects of defibrillation with the goal to optimize the procedure to allow safe termination of arrhythmias with a fraction of energy requirements of current devices. For the first time, defibrillation will be formulated as an optimization problem using optimal control techniques to devise novel shock strategies. Further, techniques for the generation of microscopically accurate cardiac tissue models will be developed by applying novel strategies for segmentation and multi-modal registration allowing the fusion of image stacks obtained with different imaging modalities (histological sections and MRI). To deal with the computational burden imposed by the resulting large systems (5-50 Mio dof), parallel algebraic MG and BEM/FEM coupling techniques will be applied to render parameters studies involving whole heart bidomain simulations including a torso possible.\r\nLong term goals include advanced techniques to optimize the exploration of complex parameter spaces associated with defibrillation with OPTIM, inverse methods will be considered to compute cardiac surface potentials from electrical or optical recordings, and we will incorporate a mechanical contraction model and a fluid mechanical model to investigate electromechanical coupling and mechano-electrical feedback mechanisms and to link modelling results to clinically relevant quantities.", "en": "In this project, a realistic computer model of the heart, a Virtual Heart simulator will be developed to investigate mechanisms underlying the formation of arrhythmias, the most frequent cause of death in the industrialized world, and their termination by electrical shocks (electrical defibrillation). During the first phase, research will focus on different aspects of defibrillation with the goal to optimize the procedure to allow safe termination of arrhythmias with a fraction of energy requirements of current devices. For the first time, defibrillation will be formulated as an optimization problem using optimal control techniques to devise novel shock strategies. Further, techniques for the generation of microscopically accurate cardiac tissue models will be developed by applying novel strategies for segmentation and multi-modal registration allowing the fusion of image stacks obtained with different imaging modalities (histological sections and MRI). To deal with the computational burden imposed by the resulting large systems (5-50 Mio dof), parallel algebraic MG and BEM/FEM coupling techniques will be applied to render parameters studies involving whole heart bidomain simulations including a torso possible.\r\nLong term goals include advanced techniques to optimize the exploration of complex parameter spaces associated with defibrillation with OPTIM, inverse methods will be considered to compute cardiac surface potentials from electrical or optical recordings, and we will incorporate a mechanical contraction model and a fluid mechanical model to investigate electromechanical coupling and mechano-electrical feedback mechanisms and to link modelling results to clinically relevant quantities." }, "begin_planned": "2006-12-01T01:00:00+01:00", "begin_effective": "2007-05-01T02:00:00+02:00", "end_planned": "2009-11-30T01:00:00+01:00", "end_effective": "2011-04-30T02:00:00+02:00", "assignment": "2007-05-09T13:44:14+02:00", "program": 67, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 2, "manager": 50966, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "F32", "ethics_committee": null, "edudract_number": null, "persons": [ "1260-50966-10", "1260-51753-12", "1260-51502-12", "1260-50967-12" ] }, { "id": 2118, "title": { "de": "Antitumor-Aktivität bioaktiver Wirkstoffe in chemoresistenten Tumoren: Apoptose in Medullären Schilddrüsencarcinomen", "en": "Antitumor-Aktivität bioaktiver Wirkstoffe in chemoresistenten Tumoren: Apoptose in Medullären Schilddrüsencarcinomen" }, "short": "APOPTOSE_MEDULL_SCHILDDRÜSCARC", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-06-01T02:00:00+02:00", "begin_effective": "2011-03-01T01:00:00+01:00", "end_planned": "2009-11-30T01:00:00+01:00", "end_effective": "2011-09-30T02:00:00+02:00", "assignment": "2010-02-12T11:41:30+01:00", "program": null, "subprogram": null, "organization": 14014, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 555, "title": { "de": "CARE-MAN: Health care by biosensor measurement and networking", "en": "CARE-MAN: Health care by biosensor measurement and networking " }, "short": "CARE-MAN", "url": null, "abstract": { "de": "Care-Man (Health CARE by Biosensor Measurements And Networking), intends to provide a validated, intelligent, next-generation diagnostic system based on biosensor technology with new detection capabilities and integrated sample-handling to address the most common diagnostic problems in the EU. \r\n\r\nThe objective of the project is to improve patient care by introducing a multianalyte system that will allow to substitute sequential measurements of key analytes with a parallel setup. This multianalyte approach will simplify the diagnostic procedure by obtaining results at the point-of-care (at first physician-patient contact) and shall be designed for use in hospitals and, in the future, also in doctors practises or for postoperative bedside home surveillance. \r\nMajor activities of the project will be related to diagnostic improvement in cardiovascular disease, cancer, inflammation and sepsis, coagulation disorders, and thyroid disorders.\r\n", "en": "Care-Man (Health CARE by Biosensor Measurements And Networking), intends to provide a validated, intelligent, next-generation diagnostic system based on biosensor technology with new detection capabilities and integrated sample-handling to address the most common diagnostic problems in the EU. \r\n\r\nThe objective of the project is to improve patient care by introducing a multianalyte system that will allow to substitute sequential measurements of key analytes with a parallel setup. This multianalyte approach will simplify the diagnostic procedure by obtaining results at the point-of-care (at first physician-patient contact) and shall be designed for use in hospitals and, in the future, also in doctors practises or for postoperative bedside home surveillance. \r\nMajor activities of the project will be related to diagnostic improvement in cardiovascular disease, cancer, inflammation and sepsis, coagulation disorders, and thyroid disorders.\r\n" }, "begin_planned": "2005-12-24T01:00:00+01:00", "begin_effective": "2005-11-01T01:00:00+01:00", "end_planned": "2009-12-24T01:00:00+01:00", "end_effective": "2010-10-31T02:00:00+02:00", "assignment": "2005-11-14T01:00:00+01:00", "program": 21, "subprogram": "TP3 - Nanotechnologies", "organization": 14046, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 907, "title": { "de": "Fetale Wachstumsrestriktion und Makrosomie als folge fetaler Hypo- und Hyperglykämie", "en": "Fetale Wachstumsrestriktion und Makrosomie als folge fetaler Hypo- und Hyperglykämie" }, "short": "Fetale Wachstumsrestriktion", "url": null, "abstract": { "de": "Intra-uterine growth restriction (IUGR) describes newborn that did not reach their genetically determined growth potential. It occurs in 3-7% of deliveries. It is associated with significantly increased perinatal morbidity and mortality as well as cardiovascular disease and glucose intolerance in adult life. IUGR is accounted for by reduced utero-placental blood flow and/or maternal hypoglycaemia. Inadequate provision of the fetus with oxygen and nutrients is the key factor for the restricted fetal growth. Risk factors such as smoking and drug abuse, maternal malnutrition and well controlled diabetes (with insulin therapy) enhance the risk of IUGR. Nevertheless, in most cases the aetiology of IUGR remains unknown.\r\n\r\nThe fetal insulin/IGF system regulates placental processes and functions that are disturbed in IUGR and macrosomia.\r\n\r\nThis study aims to address two key aspects: \r\n1. The impact of fetal insulin/IGF levels on placental cells, \r\n2. Metabolic (e.g., glucose) and hormonal (e.g., insulin/IGFs) changes that may account for altered IGF1 and IGF2 levels in the fetal circulation\r\n", "en": "Intra-uterine growth restriction (IUGR) describes newborn that did not reach their genetically determined growth potential. It occurs in 3-7% of deliveries. It is associated with significantly increased perinatal morbidity and mortality as well as cardiovascular disease and glucose intolerance in adult life. IUGR is accounted for by reduced utero-placental blood flow and/or maternal hypoglycaemia. Inadequate provision of the fetus with oxygen and nutrients is the key factor for the restricted fetal growth. Risk factors such as smoking and drug abuse, maternal malnutrition and well controlled diabetes (with insulin therapy) enhance the risk of IUGR. Nevertheless, in most cases the aetiology of IUGR remains unknown.\r\n\r\nThe fetal insulin/IGF system regulates placental processes and functions that are disturbed in IUGR and macrosomia.\r\n\r\nThis study aims to address two key aspects: \r\n1. The impact of fetal insulin/IGF levels on placental cells, \r\n2. Metabolic (e.g., glucose) and hormonal (e.g., insulin/IGFs) changes that may account for altered IGF1 and IGF2 levels in the fetal circulation\r\n" }, "begin_planned": "2006-07-01T02:00:00+02:00", "begin_effective": "2006-07-01T02:00:00+02:00", "end_planned": "2009-12-31T01:00:00+01:00", "end_effective": "2009-12-31T01:00:00+01:00", "assignment": "2006-10-03T16:05:30+02:00", "program": 79, "subprogram": null, "organization": 14038, "category": 10, "type": 10, "partner_function": 4, "manager": 51719, "contact": 51719, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "907-51719-10" ] }, { "id": 1610, "title": { "de": "Vitamin D and new bone marker levels in breast cancer patients with and without bone metastases", "en": "Vitamin D and new bone marker levels in breast cancer patients with and without bone metastases" }, "short": "VIT_D_BONE_MARKER_LEVELS", "url": null, "abstract": { "de": "Brustkrebs (BrCa) ist die häufigste Form von Krebs bei Frauen. Das Skelettsystem ist ein bevorzugtes Ziel für Metastasen bei BrCa. Hoher Knochenumsatz erhöht das Risiko für Krankheitsprogression und Tod. Der im Knochenstoffwechsel etablierte Einfluss von Vitamin D3 könnte daher auch ein wichtiger Risikofaktor für Skelettmetastasen sein.\r\nVitamin D3 und Serummarker des Knochenstoffwechsels sollen aus einer großen retrospektiven Kohorte von BrCa-Patientinnen mit einem Pool von 5400 BrCa-Patientinnen an ausgewählten Patientinnen mit (n=1050) und ohne Knochenmetastasen in konsekutiven Serumproben ausgewertet werden. Diese Gruppen werden in Alter und Tumorstadium übereingestimmt und sowohl im Querschnitt als auch im Verlauf nach Knochenmetastasen untersucht. Wir erwarten aus dieser Auswertung neue Perspektiven für Vitamin D3 und Knochenstoffwechselmarker in Pathophysiologie, Diagnose und Verlauf von Knochenmetastasen bei Brustkrebspatientinnen.", "en": "Brustkrebs (BrCa) ist die häufigste Form von Krebs bei Frauen. Das Skelettsystem ist ein bevorzugtes Ziel für Metastasen bei BrCa. Hoher Knochenumsatz erhöht das Risiko für Krankheitsprogression und Tod. Der im Knochenstoffwechsel etablierte Einfluss von Vitamin D3 könnte daher auch ein wichtiger Risikofaktor für Skelettmetastasen sein.\r\nVitamin D3 und Serummarker des Knochenstoffwechsels sollen aus einer großen retrospektiven Kohorte von BrCa-Patientinnen mit einem Pool von 5400 BrCa-Patientinnen an ausgewählten Patientinnen mit (n=1050) und ohne Knochenmetastasen in konsekutiven Serumproben ausgewertet werden. Diese Gruppen werden in Alter und Tumorstadium übereingestimmt und sowohl im Querschnitt als auch im Verlauf nach Knochenmetastasen untersucht. Wir erwarten aus dieser Auswertung neue Perspektiven für Vitamin D3 und Knochenstoffwechselmarker in Pathophysiologie, Diagnose und Verlauf von Knochenmetastasen bei Brustkrebspatientinnen." }, "begin_planned": "2008-07-01T02:00:00+02:00", "begin_effective": "2008-07-01T02:00:00+02:00", "end_planned": "2009-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2008-08-22T12:07:22+02:00", "program": 79, "subprogram": null, "organization": 14080, "category": 10, "type": 10, "partner_function": 4, "manager": 51809, "contact": 51809, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1610-51809-10", "1610-51692-12", "1610-57544-12" ] }, { "id": 1962, "title": { "de": "Charakterisierung der Splicevarianten des GIRK1 Gens aus Brustkrebszelllinien", "en": "Charakterisierung der Splicevarianten des GIRK1 Gens aus Brustkrebszelllinien" }, "short": "Splicevarianten des GIRK1", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-07-01T02:00:00+02:00", "begin_effective": "2011-01-01T01:00:00+01:00", "end_planned": "2009-12-31T01:00:00+01:00", "end_effective": "2011-06-30T02:00:00+02:00", "assignment": "2009-10-29T15:34:59+01:00", "program": null, "subprogram": "Land Steiermark Projekt über 5.000,- Euro", "organization": 14011, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1453, "title": { "de": "Defektive DNA-Reparatur als prädisponierender Faktor zu Therapie-assoziiertem Myelodysplastischen Syndrom (t-MDS) und akuter myeloischer Leukämie (t-AML)", "en": "Defektive DNA-Reparatur als prädisponierender Faktor zu Therapie-assoziiertem Myelodysplastischen Syndrom (t-MDS) und akuter myeloischer Leukämie (t-AML)" }, "short": "MDS_AML", "url": null, "abstract": { "de": "Myelodysplastisches Syndrom (MDS) und akute myeloische Leukämie (AML) sind neoplastische Erkrankungen der hämatopoetischen Stammzelle. Die meisten Fälle dieser Erkrankungen entstehen \"de novo\", wobei der verursachende Faktor unbekannt bleibt. 5%-10% aller neu auftretenden Fälle von MDS und AML entstehen als Langzeitfolge einer Chemo- und/oder Strahlentherapie für eine primäre, oftmals maligne Erkrankung. Diese Entität wird als Therapie-assoziiertes myelodysplastisches Syndrom (t-MDS) bzw. als Therapie-assoziierte akute myeloische Leukämie (t-AML) beschrieben.\r\nDie Tatsache, dass nur 1%-10% der Patienten nach Exposition gegenüber zytotoxischen Substanzen t-MDS/t-AML entwickeln, weist auf genetische Prädisposition in der Entstehung dieser Neoplasien hin.\r\nSchwerpunkt der Forschungsarbeiten dieser Gruppe ist die Aufklärung von Prädisposition zu t-MDS/t-AML.", "en": "Myelodysplastisches Syndrom (MDS) und akute myeloische Leukämie (AML) sind neoplastische Erkrankungen der hämatopoetischen Stammzelle. Die meisten Fälle dieser Erkrankungen entstehen \"de novo\", wobei der verursachende Faktor unbekannt bleibt. 5%-10% aller neu auftretenden Fälle von MDS und AML entstehen als Langzeitfolge einer Chemo- und/oder Strahlentherapie für eine primäre, oftmals maligne Erkrankung. Diese Entität wird als Therapie-assoziiertes myelodysplastisches Syndrom (t-MDS) bzw. als Therapie-assoziierte akute myeloische Leukämie (t-AML) beschrieben.\r\nDie Tatsache, dass nur 1%-10% der Patienten nach Exposition gegenüber zytotoxischen Substanzen t-MDS/t-AML entwickeln, weist auf genetische Prädisposition in der Entstehung dieser Neoplasien hin.\r\nSchwerpunkt der Forschungsarbeiten dieser Gruppe ist die Aufklärung von Prädisposition zu t-MDS/t-AML." }, "begin_planned": "2008-02-01T01:00:00+01:00", "begin_effective": "2008-02-01T01:00:00+01:00", "end_planned": "2009-12-31T01:00:00+01:00", "end_effective": "2010-05-31T02:00:00+02:00", "assignment": "2008-01-21T18:04:04+01:00", "program": null, "subprogram": null, "organization": 14082, "category": 10, "type": 10, "partner_function": 4, "manager": 51857, "contact": 51857, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 423 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1453-51857-10" ] }, { "id": 1005, "title": { "de": "Nanoscale Functionalities for Targeted Delivery of Biopharmaceuticals", "en": "Nanoscale Functionalities for Targeted Delivery of Biopharmaceuticals" }, "short": "[Nano(Biopharmaceutics)]", "url": null, "abstract": { "de": "The present project aims at the development of innovative multidisciplinary approaches for the design, synthesis and evaluation of functionalized nanocarriers and nanoparticle-based microcarriers for the treatment of various diseases based on targeted, controlled delivery of therapeutic peptides and proteins (biopharmaceutics). \r\nThe present IP integrates the scientific activities and complementary skills of researchers coming from 13 EU countries and the state of Israel, in an attempt to ensure breakthrough advances in novel biopharmaceutics delivery systems. The Consortium consists of 12 University departments, 6 research institutes, 6 SMEs and 3 large industries. An efficient management scheme has been established to ensure the fulfillment of the IPs scientific, technological and exploitation objectives.\r\n \r\n", "en": "The present project aims at the development of innovative multidisciplinary approaches for the design, synthesis and evaluation of functionalized nanocarriers and nanoparticle-based microcarriers for the treatment of various diseases based on targeted, controlled delivery of therapeutic peptides and proteins (biopharmaceutics). \r\nThe present IP integrates the scientific activities and complementary skills of researchers coming from 13 EU countries and the state of Israel, in an attempt to ensure breakthrough advances in novel biopharmaceutics delivery systems. The Consortium consists of 12 University departments, 6 research institutes, 6 SMEs and 3 large industries. An efficient management scheme has been established to ensure the fulfillment of the IPs scientific, technological and exploitation objectives.\r\n \r\n" }, "begin_planned": "2006-01-01T01:00:00+01:00", "begin_effective": "2006-10-01T02:00:00+02:00", "end_planned": "2009-12-31T01:00:00+01:00", "end_effective": "2010-09-30T02:00:00+02:00", "assignment": "2007-01-15T14:23:27+01:00", "program": 21, "subprogram": "Priority 3: Nanotechnologies and Nanosciences, Knowledge based Mulitfunctional Materials, New Production Processes and Devices", "organization": 14046, "category": 10, "type": 10, "partner_function": 2, "manager": 51831, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1005-51831-10", "1005-51107-12", "1005-53900-12", "1005-56686-12", "1005-51756-12" ] } ] }